IDT Australia Limited (ASX:IDT)

Market Cap	19.23M -35.0%
Revenue (ttm)	20.53M +3.4%
Net Income	-2.72M
EPS	-0.01
Shares Out	427.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,923
Open	0.0440
Previous Close	0.0440
Day's Range	0.0440 - 0.0450
52-Week Range	0.0300 - 0.0720
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About IDT Australia

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the compan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1975
• Employees: 100
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IDT

Financial Performance

In fiscal year 2026, IDT Australia's revenue was 20.53 million, an increase of 3.89% compared to the previous year's 19.77 million. Losses were -2.72 million, -66.30% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error